SIRT2 and cancer: m6A modification by METTL3 stabilizes FBXO31 mRNA by binding to YTHDF1, which increases FBXO31 expression and promotes proteasome‐dependent degradation of sirtuin 2 (SIRT2), leading to cancer progression [41].